Application of MSM in preparation of medicine for preventing and treating early bacterial infection

By using dimethyl sulfone (MSM) to promote phagocytosis and upregulate iNOS expression and increase NO generation, the problem of early bacterial infection, especially drug-resistant bacteria infection in the prior art is solved, and effective against lethal dose MRSA infection is achieved Prevention and control.

CN119033740APending Publication Date: 2024-11-29CHINESE PEOPLES LIBERATION ARMY ARMY SPECIAL MEDICAL CENTER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411458603.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-18
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat early bacterial infections, especially drug-resistant bacterial infections, and the bactericidal effect of NO in the bacterial infection model is inconsistent, and non-antibiotic drugs lack new mechanisms.

Method used

Dimethyl sulfone (MSM) is used as a drug to promote the phagocytosis of bacteria by macrophages, enhance RhoB protein expression, upregulate iNOS expression in macrophages, increase the production of nitric oxide (NO), and use intraperitoneal injection or other administration methods. In preparation of drugs to prevent and treat lethal doses of MRSA infection.

Benefits of technology

MSM significantly improves the survival rate of mice, promotes the phagocytosis of bacteria by macrophages, and plays a role in killing pathogens by increasing NO production, effectively preventing and treating lethal dose MRSA infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033740A_ABST
    Figure CN119033740A_ABST
Patent Text Reader

Abstract

The invention discloses an application of MSM in preparation of a drug for preventing and treating bacterial infection.Animal experiments prove that a mouse is subjected to abdominal cavity infection with a lethal dose of MRSA and then subjected to MSM treatment, the survival rate of the mouse subjected to MSM treatment is greatly increased compared with that of a control mouse, and it is proved that the drug has a protection effect on infection of the lethal dose of MRSA, and the drug can be used for preventing and treating bacterial infection. Moreover, the medicine disclosed by the invention can promote phagocytosis of peritoneal macrophages to bacteria. An MRSA infection model is established through an animal body model and in-vitro cells, and experiments prove that the mechanism of the MRSA infection model is that in the early stage of lethal dose infection, MSM promotes killing of pathogenic bacteria by macrophages by up-regulating generation of NO. The application of the MSM in preparation of the medicine for preventing and treating bacterial infection provides a new thought and theoretical basis for early infection of lethal dose MRSA.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of MSM in the preparation of drugs for preventing and treating early bacterial infections. Background Art

[0002] The phagocytic function of the body's innate immune system plays an important role in the natural defense function. Phagocytic cells (mainly macrophages, neutrophils, and endothelial cells) maintain the body's homeostasis by engulfing and removing pathogens, apoptotic fragments, or other foreign bodies that invade the body. Macrophages from the liver, spleen, bone marrow, and loose connective tissue have stronger phagocytic ability. They can not only engulf the bodies of various microorganisms and white blood cells, but also engulf and remove cell tissue fragments and other foreign bodies that enter the body. After the phagocytes engulf foreign bodies, except for very few substances such as glass, the engulfed pathogens can be digested by the "enzymes such as bactericidal media" in the cells, or absorbed after being oxidized and decomposed by the body. If the body's phagocytic cells suddenly increase, it indicates infection with pathogenic microorganisms or foreign bodies. Macrophages will gather at the site of infection to remove foreign bodies and maintain the body's homeostasis. The membrane on the surface of macrophages mediates the phagocytosis of bacteria in a variety of ways (endocytosis, receptor-mediated phagocytosis), including surrounding and internalizing pathogens to form phagosomes, fusion of phagosomes with lysosomes, and the acidic environment, hydrolases, and active substances produced in lysosomes, such as H2O2 and nitric oxide (NO), which directly have bactericidal activity against pathogens. - The redox reactions triggered by the formation of work synergistically to kill infecting pathogens.

[0003] Nitric oxide (NO) is a gaseous free radical. Macrophage immune activation induces the production of nitric oxide synthase (iNOS). iNOS oxidizes L-arginine to produce citrulline and active free radical NO. A study in 2003 showed that after iNOS knockout mice were infected with Salmonella, bacteria in their organs proliferated massively, causing sepsis and death; while wild-type mice survived. The use of iNOS inhibitor aminoguanidine increased the bacterial load in the liver and spleen of mice by 100 times and 10 times, respectively. Studies have confirmed that iNOS knockout mice did not significantly increase intracellular Staphylococcus aureus after infection, while NOX2 knockout mice significantly increased intracellular bacteria, resulting in a higher mortality rate. This emphasizes the importance of NOX2 in fighting Staphylococcus aureus. Recent research views are that inducing ROS and inhibiting the production of NO can inhibit bacterial proliferation; simply inhibiting the production of NO rather than inducing ROS production increases tolerance to Edwardsiella infection. The existing results suggest that the bactericidal effect of NO is inconsistent in different bacterial infection models. We speculate that this may be related to the type of pathogen, different models and different detection times.

[0004] We identified the ingredients in the Hunan Dong medicine "Jiao Meigu" and screened the top 10 substances with rich content. We found that dimethyl sulfone (MSM) has the potential to be developed to promote macrophage phagocytosis. MSM is a sulfur-containing compound that provides sulfur for the synthesis of cysteine ​​and methionine. It is naturally present in various fruits, vegetables, grains and unpasteurized milk. It is a dietary supplement that can relieve pain, osteoarthritis, allergies, asthma and parasitic infections. The annual market share in the United States exceeds 15 million US dollars. Acute and subacute toxicity studies using rats and chickens showed that MSM is safe. Infections with drug-resistant bacteria are the focus of WHO's attention for a long time in the future. WHO pointed out that it is urgent to find new mechanisms for non-antibiotic drugs that do not induce resistance to resist infections with drug-resistant bacteria. None of the above studies involved the application of MSM for infections with drug-resistant bacteria. Summary of the invention

[0005] In view of the shortcomings of the prior art, the present invention proposes an application of MSM in the preparation of a drug for preventing and treating bacterial infection.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] Application of MSM in the preparation of drugs for preventing and treating early bacterial infections.

[0008] Furthermore, the early bacterial infection time is 0-6 hours.

[0009] Furthermore, the drug promotes phagocytosis of bacteria by macrophages.

[0010] Furthermore, the MSM can enhance the expression of RhoB protein.

[0011] Furthermore, the drug upregulates iNOS expression in macrophages.

[0012] Furthermore, the drug promotes phagocytosis of bacteria by increasing NO production.

[0013] Furthermore, the administration method of the drug is not limited to intraperitoneal injection.

[0014] Furthermore, the effective dosage of the drug is 500 mg / kg.

[0015] Regarding the drug, preferably, the pharmaceutical composition also includes a pharmaceutically acceptable carrier, such carriers include (but are not limited to): diluents, buffers, suspensions, emulsions, granules, encapsulations, excipients, fillers, adhesives, sprays, transdermal absorbents, wetting agents, disintegrants, absorption enhancers, surfactants, colorants, flavoring agents or adsorption carriers.

[0016] The pharmaceutical composition of the present invention can be prepared into various dosage forms as required, including but not limited to tablets, solutions, granules, patches, ointments, capsules, aerosols or suppositories.

[0017] The administration route of the pharmaceutical composition of the present invention is not limited as long as it can exert the desired therapeutic or preventive effect, including but not limited to oral administration, intravenous injection, intramuscular injection, subcutaneous injection, sublingual dissolution, rectal irrigation, nasal spray, oral spray, topical skin administration or systemic transdermal administration.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] 1) The present invention discloses the use of MSM in the preparation of an early drug for preventing and treating lethal dose MRSA infection. By using a lethal dose of MRSA to infect mice intraperitoneally and then treating them with MSM, the survival rate of mice treated with MSM is much higher than that of control mice. The experiment confirms that MSM has a protective effect on infection with a lethal dose of MRSA.

[0020] 2) The present invention studies the mechanism of MSM in preventing and treating lethal doses of MRSA infection. After treatment with MSM, the experimental results show that the amount of bacteria outside the peritoneal macrophages is reduced and the amount of bacteria inside a single cell is increased, indicating that the drug can promote the phagocytosis of bacteria by macrophages.

[0021] 3) The present invention relates to the use of MSM in the preparation of drugs for preventing and treating early lethal dose MRSA infection. By establishing MRSA infection models in animals and in vitro cells, further studies have found that its molecular mechanism is that in the early stage of lethal dose infection (3-6 hours after infection), MSM kills pathogens by increasing the production of NO. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the specific implementation of the present invention, the following will briefly introduce the drawings required for use in the specific implementation. In all the drawings, each element or part is not necessarily drawn according to the actual scale.

[0023] Figure 1 MSM has a protective effect on the survival of mice infected with a lethal dose of MRSA.

[0024] Figure 2 MSM did not increase the number of peritoneal macrophages in mice infected with a lethal dose of MRSA.

[0025] Figure 3 MSM increased the number of bacteria phagocytosed by a single peritoneal macrophage when mice were infected with a lethal dose of MRSA.

[0026] Figure 4The effect of MSM treatment on phagocytosis of MRSA bacteria was evaluated in peritoneal macrophages.

[0027] Figure 5 The effect of MSM treatment on phagocytosis of fluorescent microspheres was evaluated in peritoneal macrophages.

[0028] Figure 6 The effect of MSM on the phagocytosis of fluorescent microspheres was evaluated by treating RAW264.7 macrophages with different concentrations (1 MOI).

[0029] Figure 7 The effect of MSM (10mM, 1MOI) at different treatment times on the phagocytosis of fluorescent microspheres by RAW264.7 macrophages.

[0030] Figure 8 RAW264.7 macrophages were treated with MSM (10 mM) and different MOIs of MRSA bacteria to evaluate their effects on the phagocytosis of fluorescent microspheres.

[0031] Fig. 9 The up-regulation of RhoB expression on the cell membrane in macrophages by MSM; 9A is the QPCR analysis of RhoB mRNA expression in RAW264.7 cells treated with MSM; 9B is the (B) immunoblotting analysis of RhoB protein expression at different time points in peritoneal macrophages of mice treated with MSM. 9C is the immunofluorescence analysis of the localization of RhoB protein in RAW264.7 cells treated with MSM; 9D is the statistical result of the fluorescence intensity analysis in 9C; 9E is the immunoblotting analysis of the expression of RhoB protein in the cytoplasm and cell membrane at different time points in peritoneal macrophages of mice treated with MSM.

[0032] Fig.10 F4 / 80 for MSM + CD11b + iNOS expression in double-positive macrophages.

[0033] Fig.11 MSM upregulates NO secretion in macrophages and promotes their killing of pathogens. DETAILED DESCRIPTION

[0034] Source of reagents:

[0035] MRSA (Methicillin-resistant Staphylococcus aureus, ATCC43300) strain: purchased from China Culture Collection.

[0036] C57BL / 6J mice were purchased from Beijing Spectro Biotechnology Co., Ltd.

[0037] RAW264.7 (CL-0190) and THP-1 (CL-0233) were purchased from Wuhan Prosai Life Science Co., Ltd.

[0038] MSM (Methylsulfonylmethane): purchased from #M81705.

[0039] Fluorescent microspheres (Fluorescein isothiocyanate-dextran): purchased from #46945.

[0040] Example 1 Study on the effect of MSM on lethal doses of MRSA infected mice

[0041] A lethal dose of MRSA (2×10 8 cfu / mouse) were injected intraperitoneally into infected mice at 0, 1, 3, 6, and 12 hours, and the mice were treated with MSM prepared with normal saline at a concentration of 500 mg / kg. Figure 1 As shown in the results, compared with untreated mice (MRSA), the survival rate of mice treated with MSM (MSM+MRSA) was much greater than that of untreated mice, indicating that MSM has a protective effect against lethal dose MRSA infection.

[0042] Example 2 Detection of the number of peritoneal macrophages and their ability to phagocytose bacteria at different time points

[0043] A lethal dose of MRSA (2×10 8 cfu / mouse) were injected intraperitoneally into infected mice at 0, 1, 3, 6, and 12 hours, and the mice were treated with MSM prepared with normal saline at a concentration of 500 mg / kg. The number of peritoneal macrophages in infected mice at different time points was detected. The results are shown in Figure 2 As shown in the figure, the number of peritoneal cells in the MSM treatment group (MRSA+MSM) was less than that in the MRSA infection group (MRSA). During MRSA infection, the number of neutrophils or peritoneal macrophages chemotactic to the peritoneal cavity did not increase significantly, indicating that MSM had no significant effect in promoting cell chemotaxis or proliferation.

[0044] Detection of in situ phagocytosis of bacteria by macrophages in animal models: Peritoneal cells of model mice were further isolated, and control (mice without any treatment), MRSA (2×10 8 cfu / mouse infected with MRSA intraperitoneally) for 6 hours, and MRSA+MSM (2×10 8After MRSA was injected into the left groin to infect mice, 500 mg / kg MSM was injected into the right groin to treat for 6 hours, and adherent culture was performed for 2 hours. Non-adherent cells were washed away (the remaining adherent cells were peritoneal macrophages), and extracellular bacteria were removed by vancomycin treatment. The same number of peritoneal macrophages were taken for lysis, and 100 μL was spread on LB solid medium at 37 degrees Celsius with a coating rod and inverted overnight culture to observe the amount of phagocytic bacteria in the cells; the results are shown in Figure 3 As shown in the figure, it can be seen that the peritoneal macrophages of mice in the MSM+MRSA group phagocytized more bacteria; and the amount of bacteria phagocytized by a single cell was also larger.

[0045] Detection of primary macrophages phagocytosis of bacteria in vitro: peritoneal macrophages of wild-type mice were removed, resuspended in complete culture medium, and primary peritoneal macrophages were planted in a 6-well cell culture plate at 0.8×10^6 cells / well, and cultured overnight at 37°C and 5% CO2; MRSA was added at an MOI of 2.5, and the plates were grouped into single MRSA infection wells and MRSA+MSM (10mM) wells, with 3 replicates in each group, and cultured for 3 hours at 37°C and 5% CO2; the supernatant was collected for subsequent plating to evaluate the amount of extracellular bacteria; 1 mL PBS was added to each well for rinsing 3 times, and 1 mL PBS (containing 2 mg / mL vancomycin) was incubated at 37°C and 5% CO2 for 30 minutes to completely kill extracellular MRSA; the supernatant was discarded, and the cells were frozen and thawed twice at -80°C / 37°C to completely lyse the cells. The lysate was resuspended in 1 mL of saline per well and collected for later use; the collected supernatant and lysate were diluted 1000 times and 100 μL was evenly spread on a 60 mm culture dish containing LB solid culture medium with a coating rod, and inverted cultured at 37°C overnight to evaluate the amount of intracellular bacteria. The results are shown in Figure 4 As shown in the figure, it can be seen that when the same cfu of MRSA infects the same number of peritoneal macrophages, the amount of extracellular MRSA bacteria in peritoneal macrophages treated with MSM is reduced, and the amount of bacteria in a single cell is increased compared with cells not treated with MSM; this indicates that after primary peritoneal macrophages are treated with MSM, the number of bacteria in the cell culture supernatant phagocytosed by a single macrophage is greater, and the amount of bacteria remaining in the cell culture supernatant is less.

[0046] Example 3: Using fluorescent microspheres (fluorescein isothiocyanate-dextran, Sigma, #46945) to study phagocytosis after MSM treatment

[0047] Detection of phagocytosis of fluorescent microspheres by primary peritoneal macrophages in each group of animal models: Primary peritoneal macrophages of each model mouse Control, MRSA infection for 6 hours, and MRSA+MSM treatment for 6 hours in Example 2 were isolated and phagocytized with fluorescent microspheres for 3 hours. Unphagocytized fluorescent microspheres were washed away with PBS, and the FITC channel was detected by flow cytometry. The results are shown in the figure. Figure 5 As shown in the figure, it can be seen that the percentage of macrophages that phagocytized fluorescent microspheres in the primary peritoneal macrophages of mice in the MRSA infection group and the MRSA+MSM treatment group was increased compared with the primary peritoneal macrophages of mice without any treatment. However, there was no significant difference in the percentage of primary peritoneal macrophages of mice infected with MRSA alone that phagocytized fluorescent microspheres compared with the primary peritoneal macrophages of mice treated with MRSA+MSM. However, the FITC fluorescence intensity of primary peritoneal macrophages in the MRSA+MSM treatment group was higher than that of primary peritoneal macrophages in mice infected with MRSA alone. This shows that the percentage of peritoneal macrophages that phagocytized bacteria after MSM treatment did not change significantly compared with that of mice infected with MRSA alone. However, the mean fluorescence intensity MFI of single cells phagocytized microspheres increased significantly, indicating that MSM promoted single peritoneal macrophages to phagocytize more fluorescent microspheres.

[0048] Detection of phagocytosis of fluorescent microspheres by macrophage RAW264.7 cell line treated with different concentrations of MSM: RAW264.7 cells in the cell culture dish were collected, resuspended and counted according to 2×10 5 Cells were planted in cells / well; each treatment was repeated for more than 3 wells, and cultured overnight at 37°C and 5% CO2; MRSA (1MOI) and MSM (0mM, 0.01mM, 0.1mM, 1mM, 10mM, 100mM) were added the next morning, where NC refers to the RAW264.7 cell line without any treatment; the other cell lines were all infected with MRSA; MSM (0mM) refers to only MRSA infection without MSM treatment. The cell model was established for 3 hours, and the residual bacteria and MSM in the wells were washed off, and 80μL / well of 1×PBS-diluted fluorescein isothiocyanate-dextran (150:1) was added and cultured at 37°C and 5% CO2 for 3 hours. The unbound fluorescent microspheres were washed away with PBS, and the FITC channel (reflecting the phagocytosis of fluorescent microspheres) was detected by flow cytometry; the results are shown in Figure 6 As shown in the figure, it can be seen that the fluorescence intensity of FITC gradually increased from the concentration of 0.01 mM after adding MSM, indicating that different doses of MSM promoted the phagocytosis of fluorescent microspheres by RAW264.7 macrophages.

[0049] Detection of phagocytosis of fluorescent microspheres by macrophage RAW264.7 cell line treated with MRSA and MSM at different times: In addition, MRSA (1MOI) and MSM (10mM) were used to establish the cell model for 0, 1, 2, 3, and 6 hours. The residual bacteria and MSM in the wells were washed with PBS, and 80μL / well of 1×PBS-diluted fluorescein isothiocyanate-dextran (150:1) was added and cultured at 37°C and 5% CO2 for 3 hours. The unbound fluorescent microspheres were washed with PBS, and the fluorescent phagocytosis was detected by flow cytometry. The results are as follows Figure 7 As shown in the figure, it can be seen that the ability of macrophage RAW264.7 cell line to phagocytose fluorescent microspheres increased after MRSA and MSM treatment for 1, 2, and 3 hours, but its phagocytic ability decreased at 6 hours, indicating that MSM promoted the phagocytosis of fluorescent microspheres by RAW264.7 macrophage cell line in the early stage of infection (1-3 hours).

[0050] Detection of phagocytosis of fluorescent microspheres by macrophage RAW264.7 cell line treated with different doses of MRSA: MRSA (0.001MOI, 0.01MOI, 0.1MOI, 1MOI, 10MOI) and MSM (10mM) were used to establish the cell model for 3 hours, the residual bacteria and MSM in the wells were washed away, 80μL / well of 1×PBS diluted fluorescein isothiocyanate-dextran (150:1) was added and cultured at 37℃, 5% CO2 for 3 hours, PBS was used to wash away the unbound fluorescent microspheres, and the fluorescent phagocytosis was detected by flow cytometry. The results are shown in the figure. Figure 8 As shown in the figure, it can be seen that when the RAW264.7 cell line is treated with different doses of MRSA, the larger the dose, the more fluorescent microspheres are phagocytosed, indicating that after MSM treatment, different MRSA bacterial concentrations within a certain range can promote the phagocytosis of fluorescent microspheres by the RAW264.7 macrophage cell line.

[0051] Example 4 Detection of RhoB protein expression in mice infected with MRSA and treated with MSM

[0052] A lethal dose of MRSA (2×10 8 cfu / mouse) were injected intraperitoneally into infected mice at 0, 1, 3, 6, and 12 hours. Mice were treated with MSM (500 mg / kg) prepared with normal saline. Mice infected with MRSA and treated with MSM (10 mM) were tested at the same time. The expression of RhoB protein, a phagocytosis-related molecule, in peritoneal macrophages was detected at different time points. The results are as follows Fig. 9 A. It was found that RhoB mRNA expression in peritoneal macrophages reached a peak 2 hours after the model was established. At the same time, RhoB protein expression in peritoneal macrophages reached a peak 4.5 hours after the model was established, and protein expression decreased after 6 hours. Fig. 9B. Immunofluorescence was used to detect the main expression location of RhoB. RHOB (A01550-1, Boster) antibody and DAPI (C1006, Biyuntian) blue were used to mark the cell nucleus. Merge was used for the co-localization analysis of RHOB and the cell nucleus. It was found that RHOB (purple) protein was mainly expressed in the cell membrane and cytoplasm. The results are as follows Fig. 9 C; Studies have confirmed that RhoB is expressed in membrane structures (including cell membrane, mitochondrial membrane, nuclear membrane, etc.) and cytoplasm. We intend to further confirm whether the cell membrane or mitochondrial membrane has the highest expression abundance in this study. We will separate cell membrane and cytoplasmic components. ATPase is a marker of cell membrane, which can indicate whether the cell membrane separation is successful. The experimental results are as follows Fig. 9 D, indicating that RhoB protein is highly expressed on the cell membrane.

[0053] Example 5: Study on the mechanism of MSM in clearing pathogens

[0054] It is intended to further clarify how MSM promotes the killing of pathogens and study the acid expression in peritoneal macrophages of mice treated with MSM. Specifically, the mouse model in Example 2 was used: a lethal dose of MRSA (2×10 8 cfu / mouse) were injected intraperitoneally into infected mice at 0, 1, 3, 6, and 12 hours. The mice were treated with MSM at a concentration of 500 mg / kg using normal saline. The acid expression in the peritoneal macrophages of the MSM-treated mice was detected. The results are as follows: Fig.10 As shown in A, from the abundance and intensity of green fluorescence expression in the figure, it can be seen that there is no significant difference in the expression of green fluorescent protein in the peritoneal macrophages of mice infected with MRSA alone and mice treated with MRSA+MSM, indicating that there is no significant change in the pH value of peritoneal macrophages in the single infection group and the MSM combined with MRSA infection group.

[0055] Further study was conducted to investigate the expression of F4 / 80 in cells at different time points of 0, 1, 3, and 6 hours after MRSA infection. + CD11b + The expression of iNOS in macrophages was as follows Fig.10 B, 10C, flow cytometry results show that F4 / 80 + CD11b + iNOS + The proportion of macrophages increased after MSM treatment, but did not change significantly at 1 hour and 6 hours after infection ( Fig.10 B), and MSM up-regulated F4 / 80 + CD11b + iNOS + There was a statistically significant difference in the proportion of macrophages ( Fig.10C); The mean fluorescence intensity of iNOS in peritoneal macrophages treated with MSM at different times of MRSA infection was higher than that in the MRSA group alone. Fig.10 D, MSM up-regulates iNOS expression in macrophages.

[0056] Further analysis of F4 / 80 + CD11b + The expression of iNOS in single positive cells was as follows Fig.10 E, shows that there is no significant difference in the expression of iNOS in single positive cell subsets.

[0057] The above study confirmed that MSM promotes the expression of iNOS in macrophages. iNOS (inducible nitric oxide synthase) is a key enzyme for the synthesis of NO in cells. It is intended to further clarify whether MRSA regulates the secretion of NO by macrophages when mice are infected with MRSA. The results are as follows Fig.11 As shown in A, the NO content in the peritoneal lavage fluid of MRSA-infected mice treated with MSM was compared with that of mice infected with MRSA alone at 0, 1, 3, and 6 hours. It was found that the NO content in the peritoneal lavage fluid of the MSM-treated group was significantly increased at 1, 3, and 6 hours, while it was significantly reduced at 12 hours. In order to further clarify whether MSM exerts a bactericidal effect through NO during MRSA infection, an MRSA infection model was established in vitro using RAW264.7 cells, and MSM, iNO S highly selective inhibitor 1400w (N-[3-(Aminomethyl)benzyl]acetamidine, inhibiting NO production), and NO donor SNP (Sodium Nitroprusside, promoting the amount of NO) were added to study the number of intracellular bacteria. The results are shown in Fig.11 As shown in Figure B, it can be seen from the figure that when MRSA is infected alone, there are still a large number of MRSA bacteria infected by macrophages after phagocytosis and bactericidal effects; after adding MSM treatment, the total number of bacteria decreased; when 1400w of iNOS highly selective inhibitor was added to the cells, the number of MRSA bacteria was still large; this shows that when NO donor SNP was added to the cells, the number of MRSA bacteria decreased, and there was no significant difference with the MSM treatment group. The statistical results of the number of bacteria can be found in Fig.11 C. The above studies have confirmed that MSM plays a role in eliminating pathogens by promoting NO production.

[0058] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments. On the basis of the present invention, some modifications or improvements can be made thereto, which is obvious to those skilled in the art. Therefore, these modifications or improvements made on the basis of not departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

Claims

1. Application of MSM in the preparation of drugs for preventing and treating early bacterial infections.

2. The use according to claim 1, characterized in that: The early bacterial infection time is 0-6 hours.

3. The use according to claim 1, characterized in that: The drug promotes phagocytosis of bacteria by macrophages.

4. The use according to claim 1, characterized in that: The MSM can enhance the expression of RhoB protein.

5. The use according to claim 1, characterized in that: The drug upregulates iNOS expression in macrophages.

6. The use according to claim 1, characterized in that: The drug promotes the killing of bacteria by increasing NO production.

7. The use according to any one of claims 1 to 6, characterized in that: The drug includes a pharmaceutically acceptable carrier.

8. The use according to claim 7, characterized in that: The administration method of the drug is not limited to intraperitoneal injection.

9. The use according to claim 8, characterized in that: The effective dosage of the drug is 500 mg / kg.